Literature DB >> 9467567

A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy.

A W Kung1, B M Jones.   

Abstract

Remission of Graves' disease (GD) during pregnancy with recrudescence after delivery is commonly observed. However, as pregnancy is associated with type 2 rather than type 1 cytokine production, a decrease in thyroid-stimulating antibody (TSAb) activity alone is unlikely to account for the remission during pregnancy. We hypothesized that a change in the antibody characteristics may occur as pregnancy advances. Fifteen women were studied in the first, second, and third trimesters of pregnancy and 4 months postpartum. TSH receptor antibodies were determined using human thyroid cell cultures, and lymphocyte subsets were measured by flow cytometry. Median TSAb (determined by cAMP release) decreased from 280% (96-3200) to 130% (range, 35-350; P < 0.05) during pregnancy, but no significant change was noted with the TSH binding inhibitory antibody (TBII; determined by RRA). Thyroid stimulation-blocking antibody (TSBAb; inhibition of TSH-stimulated cAMP release) increased from 16 +/- 9% to 43 +/- 16% (mean +/- SD; P < 0.005). The increase in TSBAb was observed even among those patients who were in clinical remission before pregnancy. Overall, a negative correlation was observed between TSBAb activities and free T4 levels during pregnancy (r = -0.279; P < 0.05). Reciprocal changes in TSAb, TBII, and TSBAb levels were observed in the seven patients who relapsed during the postpartum period. In comparison, the healthy pregnant women (n = 14) were all negative for TSAb, TBII, and TSBAb throughout pregnancy. The absolute number of T lymphocytes, T helper cells, and natural killer cells, but not B cells, decreased significantly during pregnancy in both healthy women and GD patients. GD patients had significantly more CD5+ B cells at all stages of pregnancy compared to controls. In conclusion, a change in specificity from stimulatory to blocking antibodies was observed in GD patients during pregnancy and may contribute to the remission of GD during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467567     DOI: 10.1210/jcem.83.2.4598

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Management of hyperthyroidism in pregnancy.

Authors:  John H Lazarus
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

Review 2.  Pre-conception counselling in graves' disease.

Authors:  John H Lazarus
Journal:  Eur Thyroid J       Date:  2012-02-29

Review 3.  Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2013-01       Impact factor: 6.568

4.  Performance and Specificity of 6 Immunoassays for TSH Receptor Antibodies: A Multicenter Study.

Authors:  Tanja Diana; Christian Wüster; Paul D Olivo; Angelica Unterrainer; Jochem König; Michael Kanitz; Artur Bossowski; Brigitte Decallonne; George J Kahaly
Journal:  Eur Thyroid J       Date:  2017-08-08

Review 5.  Thyroid-Stimulating Hormone Receptor Antibodies in Pregnancy: Clinical Relevance.

Authors:  Ines Bucci; Cesidio Giuliani; Giorgio Napolitano
Journal:  Front Endocrinol (Lausanne)       Date:  2017-06-30       Impact factor: 5.555

6.  Anti-TSH receptor antibodies (TRAb): Comparison of two third generation automated immunoassays broadly used in clinical laboratories and results interpretation.

Authors:  José María López Ortega; Pilar Salvador Martínez; Delia Acevedo-León; Núria Estañ Capell
Journal:  PLoS One       Date:  2022-07-25       Impact factor: 3.752

7.  Thyroid autoantibodies in pregnancy: their role, regulation and clinical relevance.

Authors:  Francis S Balucan; Syed A Morshed; Terry F Davies
Journal:  J Thyroid Res       Date:  2013-04-18

8.  Microchimerism in graves' disease.

Authors:  Juan C Galofré
Journal:  J Thyroid Res       Date:  2012-04-05

Review 9.  Thyrotropin Receptor Blocking Antibodies.

Authors:  Tanja Diana; Paul D Olivo; George J Kahaly
Journal:  Horm Metab Res       Date:  2018-10-04       Impact factor: 2.936

Review 10.  The Clinical Value and Variation of Antithyroid Antibodies during Pregnancy.

Authors:  Chuyu Li; Jing Zhou; Zengshu Huang; Xinyao Pan; Wingting Leung; Lijia Chen; Yanzhi Zhang; Lan Wang; Yizhen Sima; Hans-Jürgen Gober; Na Zhang; Xuemin Qiu; Lisha Li; Liang Guan; Ling Wang
Journal:  Dis Markers       Date:  2020-10-21       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.